Pharmaceutical care of patients with lipid metabolic disorders;Pharmazeutische betreuung von patienten mit fettstoffwechselstörungen

Pharmazeutische Zeitung

Volumn 148, Issue 43, 2003, Pages 30-35

  Birnbaum, Ulrike ^a   Schaefer, Marion ^a   Verheyen, Frank ^b   Schulz, Martin ^c   Mast, Oliver ^d   Evers, Thomas ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Unternehmensentwicklung   (Germany)

^c ABDA Bundesvereinigung Deutscher Apothekerverbande   (Germany)

^d Hestia Health Care GmbH   (Germany)

^e BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

BODY MASS; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; HUMAN; LIPID METABOLISM; METABOLIC DISORDER; PHARMACEUTICAL CARE; RISK FACTOR; SHORT SURVEY;

EID: 0242323537     PISSN: 00317136     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (19)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 285 (2001) 2486-97.
2. American Heart Association: Heart and stroke statistical update. Dallas 2001.
3. Arzneimittelkommission der deutschen Ärzteschaft: Empfehlungen zur Therapie von Fettstoffwechselstörungen. Köln 1999.
4. Downs, J. R., Clearfield, M., Weis, S., et al., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-22.
5. Scandiavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-9.
6. Shepherd, J., Cobbe, S. M., Ford, I., et al., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-7.
7. Snacks, F. M., Pfeffer, M. A., Moye, L. A., et al., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 355 (1996) 1001-9.
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in ischaemic Disease (LIPID) Study Group. N Engl J Med 339 (1998) 1349-57.
9. Tsuyuki, R. T., Johnson, J. A., Teo, K. K., et al., A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 162 (2002) 1149-55.
10. Nola, K. M., Gourley, D. R., Portner, T. S., et al., Clinical and humanistic outcomes of a lipid management program in the community pharmacy setting. J Am Pharm Assoc 40 (2000) 166-73.
11. Shibley, M. C., Pugh, C. B., Implementation of pharmaceutical care services for patients with hyperlipidemias by independent community pharmacy practitioners. Ann Pharmacother 31 (1997) 713-9.
12. Simpson, S. H., Johnson, J. A., Tsuyuki, R. T., Economic impact of community pharmacist intervention in cholesterol risk management: an evaluation of the study of cardiovascular risk intervention by pharmacists. Pharmacotherapy 21 (2001) 627-35.
13. Bluml, B. M., Mc Kenney, J. M., Cziraky J., et al., Pharmaceutical care services and results in project IMPACT: Hyperlipidaemia. J Am Pharm Assoc 40 (2000) 157-65.
14. Deutsche Gesellrschaft zur Bekämpfung von Fettstoffwechselstö rungen und ihren Folgeerkrankungen DGFF (Lipid-Liga) e.V.: Diagnostik u nd Therapie von Fettstoffwechselstörungen in der hausärztlichen Praxis. 1999.
15. Staples, B., Bravender, T., Drug compliance in adolescents. Pediatr Drugs 4 (2002) 503-13.
16. Claxton, A. J. Cramer, J., Pierce, C., A systematic review of the associations between dose regimes and medication compliance. Clin Ther 23 (2001) 1296-1310.
17. Horne, R., Representation for medication and treatment advances in theory and measurement. In: Petrie K, Weinmann J (Hrsg.): Perceptions of health and illness. Harwood Academic Publishers, Amsterdam (1997) 155-88.
18. N.N.: Neuverordnung eines Statins. Datenbasis IMS Mediplus, 1999.
19. Simons, L. A., Levis, G., Simons, J., Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 164 (1996) 208-11.